Vector-based Cancer Vaccine Development Solutions

Q: What is the main advantage of bacterial vectors over viral vectors?

Bacterial vectors like Listeria can be easily administered repeatedly without being neutralized as quickly as some viral vectors. Furthermore, intracellular bacteria can actively target the cytosol of APCs, directly feeding antigens into the MHC Class I pathway for potent CD8+ T cell priming.

The advantages of vector-based vaccines include 1) Multiple delivery of TAAs at one time; 2) Vector itself is immunogenic, boosting the overall immune response; 3) Speedy and easy production. Besides virus vector, unharmful bacteria, yeast cells or other structures can also be used as vector to deliver the TAAs into the body.

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for vector-based cancer vaccines. We guarantee the finest results for our customers all over the world.

Get a Quote

Navigating the Complexities of Vector Design

Developing effective vector-based vaccines requires balancing immunogenicity with safety and manufacturing feasibility. Key challenges we address include:

▶ Pre-existing Immunity: Many patients have antibodies against common viral vectors (e.g., Ad5). We utilize Rare Serotypes & Non-Human Vectors (e.g., Chimpanzee Adenovirus, Arenavirus) to evade neutralization.
▶ Safety Profile: Live vectors pose replication risks. We specialize in engineering Replication-Deficient & Attenuated Strains (e.g., Listeria ΔactA) that retain immunogenicity without pathogenicity.
▶ Cargo Capacity: Large or multiple antigens can destabilize vectors. Our optimization includes Gene Insertion Strategy and promoter selection to accommodate complex payloads like poly-epitopes.
▶ Manufacturing Yield: High-titer production is often a bottleneck. We provide scalable High-Producer Cell Lines and purification protocols for consistent research-grade vector supply.

Consult Our Experts

Our Solutions

We provide a broad spectrum of vector technologies, allowing you to select the optimal delivery system for your specific tumor antigen and therapeutic goals:

Viral Vector Construction

Development of recombinant viruses including Adenovirus (Ad), Lentivirus (LV), Poxvirus (Vaccinia/MVA), Alphavirus, and Arenavirus with optimized transgene expression cassettes.

Bacterial Vector Engineering

Engineering of intracellular bacteria like Listeria monocytogenes and Salmonella to deliver antigens directly to the host cell cytosol, potently stimulating MHC Class I presentation.

Yeast-based Vaccine Design

Utilization of heat-killed Saccharomyces cerevisiae (yeast) expressing tumor antigens. Yeast beta-glucans act as natural adjuvants, activating dendritic cells via Dectin-1 receptors.

Oncolytic Virus Modification

Engineering of Newcastle Disease Virus (NDV), HSV-1, and Measles Virus to selectively replicate in and lyse tumor cells while expressing therapeutic transgenes.

Featured Development Services

Creative Biolabs offers specialized modules categorized by vector type to accelerate your vaccine research:

Viral Vectors for Cancer Therapy

View All Viral Vectors

Adenovirus Based Vaccines

Adenoviruses have long been used as a gene therapy vehicle. We provide serotype selection and gene insertion strategies for optimal TAA expression.

Learn More →

Poxvirus Based Vaccines

Poxviruses (Vaccinia, Canarypox, Fowlpox) are safe and effective at inducing immune responses. We offer vector construction and attenuation services.

Learn More →

Alphavirus Based Vaccines

Alphavirus vectors avoid neutralizing antibody issues, allowing for multiple injections. We design replicons for high-level antigen expression.

Learn More →

Lentivirus Based Vaccines

Lentiviral vectors (LVs) are effective delivery vehicles capable of transducing non-dividing cells. We focus on safety-enhanced, self-inactivating designs.

Learn More →

NDV Based Vaccines

Newcastle Disease Virus (NDV) is explored as both a direct vaccine vector and an oncolysate platform. We engineer strains for enhanced oncolytic activity.

Learn More →

HSV-1 Based Vaccines

Replication-incompetent HSV-1 vectors are developed for their large cargo capacity, allowing the delivery of multiple or large tumor antigens.

Learn More →

Measles Virus Based Vaccines

We provide genetic engineering of oncolytic measles viruses, including retargeting strategies and insertion of therapeutic transgenes.

Learn More →

Arenavirus Based Vaccines

Arenavirus vectors (e.g., LCMV) gain attention for low pre-existing immunity and high expression levels. We offer custom vector engineering services.

Learn More →

Bacterial Vectors for Cancer Vaccines

Listeria Monocytogenes Based Vaccines

Intracellular Listeria vectors effectively deliver antigens to the APC cytosol. We engineer attenuated strains to maximize safety and CD8+ T cell priming.

Learn More →

Salmonella Based Vaccines

Salmonella vectors induce potent innate and cellular immunity. We optimize passenger antigen presentation within a favorable cytokine environment.

Learn More →

Fungal Vectors for Cancer Vaccines

Yeast Based Vaccines

Whole recombinant yeast (Saccharomyces cerevisiae) serves as a vector to deliver TAAs. Yeast beta-glucans act as natural adjuvants to boost DC activation.

Learn More →

Streamlined Development Workflow

Our integrated pipeline accelerates the generation of research-grade vectors from design to in vivo validation:

Step 1: Vector Selection & Antigen Design

Service: Selection of the optimal vector backbone (Viral/Bacterial) based on target tissue and required immune response type. Codon optimization of the antigen gene for the specific host expression system.

Step 2: Recombinant Vector Construction

Service: Cloning of the antigen gene into the shuttle plasmid. Homologous recombination (for Adeno/Pox) or transformation (for Bacteria) to generate the recombinant vector genome.

Step 3: Rescue & Amplification

Service: Transfection of packaging cell lines (e.g., HEK293) to rescue viral particles, or culture of recombinant bacteria. Serial passaging to amplify viral titers or bacterial stocks.

Step 4: Purification & Titration

Service: Purification via CsCl gradient ultracentrifugation or chromatography. Determination of viral titer (PFU/mL or VP/mL) or bacterial CFU, and rigorous sterility/endotoxin testing.

Step 5: Preclinical Immunogenicity Study

Service: Immunization of mice models. Evaluation of antigen-specific T cell responses (ELISpot, ICS) and antibody titers. Assessment of vector biodistribution and safety.

Note: This workflow is strictly for preclinical research and development purposes.

Start Your Project

Advanced Technology Platforms

Our vector vaccine solutions are supported by specialized engineering and production platforms:

Proprietary packaging cell lines and helper plasmids for the efficient production of high-titer Adenovirus, Lentivirus, and AAV vectors. We utilize suspension culture systems for scalable upstream processing.

Suspension HEK293 culture
Helper-free packaging systems
High-titer concentration protocols

A genetic engineering platform dedicated to creating auxotrophic or virulence-attenuated bacterial strains (e.g., Listeria, Salmonella). We ensure precise deletion of pathogenicity genes while maintaining immunogenicity.

Targeted gene deletion (Red/ET recombineering)
Auxotrophic marker selection
Plasmid stability optimization

An established platform for the generation of recombinant Saccharomyces cerevisiae vaccines. Includes rapid cloning, expression verification, and standardized heat-killing protocols to prepare whole-yeast vaccine formulations.

Yeast surface display
High-density fermentation
Beta-glucan quantification

Comprehensive assays to profile the immune response induced by vector vaccines. We specialize in distinguishing anti-vector immunity from anti-tumor immunity using peptide libraries and flow cytometry.

Vector neutralization assays
Antigen-specific T-cell assays
Multiplex cytokine profiling

Viral Vector Packaging

Attenuated Bacterial Engineering

Yeast Vaccine Production

Immune Profiling

Inquire About Our Technology

Why Choose Creative Biolabs

Versatile Portfolio

One of the few providers offering Viral, Bacterial, Yeast, and Arenavirus vector platforms under one roof.

Immune Potency

Vectors are selected and engineered to act as natural adjuvants, boosting innate immunity.

Safety Engineering

Expertise in developing replication-deficient and attenuated strains for enhanced safety profiles.

Custom Solutions

Tailored vector design including promoter selection and epitope string optimization.

Request a Free Consultation

Frequently Asked Questions

Q: What is the main advantage of bacterial vectors over viral vectors?

A: Bacterial vectors like Listeria can be easily administered repeatedly without being neutralized as quickly as some viral vectors. Furthermore, intracellular bacteria can actively target the cytosol of APCs, directly feeding antigens into the MHC Class I pathway for potent CD8+ T cell priming.

Q: How do you address pre-existing immunity to viral vectors?

A: We employ several strategies: 1) Using non-human viral serotypes (e.g., Chimpanzee Adenovirus) that humans have not been exposed to; 2) Utilizing Arenavirus vectors which naturally have very low seroprevalence; 3) Using heterologous prime-boost regimens (e.g., priming with Adeno, boosting with Pox).

Q: Are your vectors replication-competent or deficient?

A: We primarily develop replication-deficient vectors (e.g., E1/E3 deleted Adenovirus, MVA) for safety reasons, as they cannot spread in the host. However, for oncolytic applications (e.g., NDV, Measles), we design replication-competent viruses that selectively replicate only in tumor cells.

Q: Why are Arenavirus vectors considered promising?

A: Arenavirus vectors (like LCMV) are non-cytolytic and do not induce neutralizing antibodies against the vector itself even after repeated administration. This allows for effective 'boosting' of the immune response, overcoming a major bottleneck of other viral platforms.

Q: What is the turnaround time for vector production?

A: Timelines vary by vector type. Generally, producing research-grade recombinant Adenovirus or Lentivirus takes about 4-6 weeks from gene synthesis to purified titered stock. Complex vectors or those requiring extensive engineering may take longer.

Ask Our Experts

Related Resources